(Q57396324)
Statements
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial (English)
0 references
May 2006
0 references
151
0 references
985-991
0 references
5
0 references